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Abstract: A series of 6-halo-3-hydroxyphenylcoumarins (resveratrol-coumarins hybrid 
derivatives) was synthesized in good yields by a Perkin reaction followed by hydrolysis. 
The new compounds were evaluated for their vasorelaxant activity in intact rat aorta rings 
pre-contracted with phenylephrine (PE), as well as for their inhibitory effects on platelet 
aggregation induced by thrombin in washed human platelets. These compounds 
concentration-dependently relaxed vascular smooth muscle and some of them showed a 
platelet antiaggregatory activity that was up to thirty times higher than that shown by 
trans-resveratrol and some other previously synthesized derivatives. 
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1. Introduction  
Coumarins (or benzopyrones) are a large family of compounds of natural and synthetic origin that 
show numerous biological activities, including cardiovascular properties [1]. For instance, 
Carbochromen (3-diethylaminoethyl-7-ethoxycarbonylmethoxy-4-methylcoumarin (Figure 1) is a 
potent specific coronary vasodilator that has been used for many years in the treatment of angina 
pectoris [2,3]. Futhermore, warfarin [3-(2-acetyl-1-phenylethyl)-4-hydroxycoumarin (Figure 1) is a 
coumarin with potent anticoagulant activity and a good pharmacokinetic profile [4].  

















trans-Resveratrol (t-RESV; 3,4',5-trihydroxy-trans-stilbene; Figure 1) is a natural phenolic 
component of Vitis vinifera L. (Vitaceae). It is abundant in the skin of the grapes and it is present in 
higher concentrations in red than in white wines. trans-Resveratrol has shown a number of biological 
activities, including protection against coronary heart disease, as a result of different effects: 
significant antioxidant activity, modulation of lipoprotein metabolism, and vasodilatatory and platelet 
antiaggregatory properties [5–8]. 
Because of their similar characteristics, it was of interest to design and synthesize hybrids that 
incorporate the nucleus of the coumarins and resveratrol molecules. In previous work, our research 
group had reported the vasorelaxant and platelet antiaggregatory activities of a series of coumarin-
resveratrol hybrids (3-arylcoumarins), bearing hydroxy or methoxy groups on the coumarin and/or on 
the 3-phenyl ring. 6-Hydroxy-3-(3’,5’-dihydroxyphenyl)coumarin showed vasorelaxant and platelet 
antiaggregatory activity higher than that of trans-resveratrol [9]. 
Based on this, and with the aim of improving the vasorelaxant and platelet antiaggregatory 
activities of resveratrol-coumarin hybrids and establishing a relationship between the structure and 
activity for this type of compounds we have studied the effects of substitution on the 3-arylcoumarin 
moiety with groups showing different steric and electronics effects. In this paper we report the 
synthesis and evaluation of a new series of 3-arylcoumarins in which the hydroxy group in the 6 
position has been changed for a halogen group, and different positions of hydroxyl group in 3-phenyl 
ring were explored. 
 




2. Results and Discussion  
The 3-phenylcoumarins 6-11 [10] were prepared from the conveniently substituted phenylacetic 
acids 1-3, the appropriate salicylaldehyde 4, 5 and dicyclohexylcarbodiimide (DCC) by a Perkin 
reaction [11–13] in dimethylsulfoxide (DMSO). These reactions gave 46%, 40%, 27%, 29%, 31% and 
33% yield, respectively. Hydrolysis of the methoxy groups [14] by treatment with HI in acetic 
acid/acetic anhydride gave the hydroxy derivatives 12, 13, 14, 15, 16 and 17 [15–16], in 28%, 70%, 
60%, 73%, 94% and 57% yield, respectively (Scheme 1). 








1 R1 = MeO; R2 = R3 = H
2 R2 = MeO; R1 = R3 = H




4 X = Cl




6 X = Cl; R1 = MeO; R2 = R3 = H
7 X = Cl; R2 = MeO; R1 = R3 = H
8 X = Cl; R3 = MeO; R1 = R2 = H
9 X = Br; R1 = MeO; R2 = R3 = H
10 X = Br; R2 = MeO; R1 = R3 = H
11 X = Br; R3 = MeO; R1 = R2 = H
a
b
12 X = Cl; R1 = OH; R2 = R3 = H
13 X = Cl; R2 = OH; R1 = R3 = H
14 X = Cl; R3 = OH; R1 = R2 = H
15 X = Br; R1 = OH; R2 = R3 = H
16 X = Br; R2 = OH; R1 = R3 = H






Reagents and conditions: (a) DCC, DMSO, 110 °C, 12h; (b) HI/AcOH/Ac2O, 0 °C to rt, 3 h. 
 
The vasorelaxant effects of compounds 12-17 were studied on pre-contracted rat aortic rings with 
endothelium [6]. The cumulative addition of t-RESV or the new compounds (1-100 μM) caused a 
concentration-dependent relaxation of the contractions induced by phenylephrine (PE, 1 μM) in intact 











Table 1. Vasorelaxant activity (IC50 in μM) of tested compounds. 
Compound PE (1 μM) 
12 36.63 ± 2.46* 
13 57.63 ± 3.87* 
14 ** 
15 48.79 ± 3.27* 
16 46.67 ± 3.13* 
17 ** 
t-RESV 3.12 ± 0.26 
* P < 0.01 versus the corresponding IC50 values of t-RESV; ** Inactive at 100 μM (highest 
concentration tested). At higher concentrations compounds precipitate. 
 
All evaluated compounds resulted less efficient than t-RESV in relaxing the contractions induced 
by PE. Furthermore, substitution with a p-hydroxy group in the 3-phenyl ring (compounds 14 and 17) 
leads to inactive compounds. Platelet aggregation studies were also performed. Compounds 12, 13 and 
17 inhibited platelet aggregation more effectively than t-RESV when thrombin (0.25 U/mL) was used 
as the stimulating agent (Table 2). 
Table 2. Antiplatelet activity (IC50 in μM) for tested compounds. 
Compound Thrombin (0.25 U/mL) 
12 91.36 ± 6.13* 




17 20.1 ± 1.35* 
t-RESV 195.50 ± 13.82 
* P < 0.01 versus the corresponding IC50 values of t-RESV; ** Inactive at 100 μM (highest 
concentration tested). At higher concentrations compounds precipitate. 
 
These results indicate that the variation of the position of the hydroxyl group on the 3-phenyl and 
the substitution with different halogen groups in the 6 position of the coumarin ring, in this type of 
molecules (resveratrol-coumarins hybrid), can give derivatives with a significantly higher 
pharmacological potency than t-RESV. This is the case for compound 13, which has a platelet 
antiaggregatory activity that is more than 32 times higher than that of t-RESV. 
3. Experimental   
3.1. General 
 
Melting points were determined in a Reichert Kofler thermopan or in capillary tubes in a Buchi 510 
apparatus, and are uncorrected. Infrared (IR) spectra were recorded in a Perkin-Elmer 1640FT 
spectrometer (KBr disks, ν in cm-1).13C and 1H spectra of samples approximately 10% solutions in 
chloroform-d, were recorder at room temperature in 5 mm o.d. tubes. TMS was used as internal 




standard, chemical shifts are expressed in ppm (δ), J in Hz. NMR spectra were recorded with a Bruker 
AMX 500 (1H-, 500 MHz; 13C-, 125 MHz) instrument. ). Mass spectra were obtained using a 
Hewlett-Packard 5988A spectrometer (70 eV). Silica gel (35-60 mesh) was used for flash 
chromatography (FC). Analytical TLC was performed on plates precoated with silica gel (Merck 60 
F254, 0.25 mm). Elemental analyses were performed with a Perkin-Elmer 240B microanalyser. 
Phenylacetic acids 1-3, salicylaldehydes 4, 5, hydriodic acid (HI), acetic acid (AcOH), acetic 
anhydride (Ac2O), dicyclohexylcarbodiimide (DCC) and dimethylsulfoxide (DMSO) were 




The studied compounds are all known and were prepared by a traditional Perkin reaction carried out 
in refluxing dimethylsulfoxide (DMSO) between conveniently substituted phenylacetic acids 1-3 and 
the corresponding salicylaldehyde 4, 5, using dicyclohexylcarbodiimide (DCC) as dehydrating agent 
(Scheme 1) [11–13]. Hydrolysis of methoxy groups [14], by treatment with HI in acetic acid/acetic 
anhydride gave the desired hydroxyl derivatives 12-17 [15–16]. 
 
6-Chloro-3-(2’-methoxy)phenylcoumarin (6). Purified by chromatography using 9:1 hexane/ethyl 
acetate as eluent; Mp: 177–179 ºC; IR (KBr): 2920, 1705, 1610, 1302, 1125, 780 cm-1; 1H-NMR 
(CDCl3) δ (ppm): 3.83 (s, 3H, CH3O), 7.00 (d, J = 8.2 Hz, 1H), 7.05 (d, J = 7.5 Hz, 1H), 7.22 (d,  
J = 8.2 Hz, 1H), 7.41 (m, 3H), 7.60 (m, 1H), 7.66 (s, 1H); 13C-NMR (CDCl3) δ (ppm): 55.7, 111.3, 
116.7, 118.2, 120.6, 121.0, 126.9, 130.0, 130.4, 130.7, 131.0, 133.8, 140.2, 152.2, 156.9, 157.1; MS 
m/z (%): 288 ([M+2]+, 33), 286 (M+, 100), 269(16), 251 (8), 240 (5), 193 (21), 152 (16), 118 (14); 
Anal. Calcd for C16H11ClO3: C, 67.03; H, 3.87. Experimental: C, 67.25; H, 3.99. 
 
6-Chloro-3-(3’-methoxy)phenylcoumarin (7). Purified by chromatography using 9:1 hexane/ethyl 
acetate as eluent; Mp: 144–146 ºC; IR (KBr): 2925, 1700, 1615, 1300, 1115, 775 cm-1; 1H-NMR 
(CDCl3) δ (ppm): 3.85 (s, 3H, CH3O), 6.96 (dd, J = 2.5; 8.2 Hz, 1H), 7.25 (m, 2H), 7.35 (m, 2H), 7.48 
(m, 2H), 7.72 (s, 1H); 13C-NMR (CDCl3) δ (ppm): 55.32, 114.2, 114.8, 117.8, 120.6, 120.8, 127.0, 
129.2, 129.5, 129.7, 131.3, 135.5, 138.5, 151.8, 159.5, 159.8; MS m/z (%): 288 ([M+2]+, 29), 286 (M+, 
100), 258(30), 215 (20), 201 (5), 152 (7); Anal. Calcd for C16H11ClO3: C, 67.03; H, 3.87. 
Experimental: C, 67.20; H, 3.95. 
 
6-Chloro-3-(4’-methoxy)phenylcoumarin (8). Purified by chromatography using 9:1 hexane/ethyl 
acetate as eluent; Mp: 194–196 ºC; IR (KBr): 2918, 1710, 1614, 1300, 1117, 779 cm-1; 1H-NMR 
(CDCl3) δ (ppm): 3.85 (s, 3H, CH3O), 6.99 (d, J = 8.9 Hz, 2H), 7.29 (d, J = 8.0 Hz, 1H), 7.48 (m, 2H), 
7.66 (d, J = 8.9 Hz, 2H), 7.71 (s, 1H); 13C-NMR (CDCl3) δ (ppm): 55.4, 113.9 (2C), 117.7, 118.3, 
120.3, 121.1, 126.8, 129.8 (2C), 130.8, 136.9, 141.1, 151.9, 156.3, 158.2; MS m/z (%): 288 ([M+2]+, 
37), 286 (M+, 100), 258(13), 243 (16), 180 (3), 152 (5); Anal. Calcd for C16H11ClO3: C, 67.03; H, 3.87. 
Experimental: C, 67.10; H, 3.99. 
 




6-Bromo-3-(2’-methoxy)phenylcoumarin (9). Purified by chromatography using 9:1 hexane/ethyl 
acetate as eluent; Mp: 183–185 ºC; IR (KBr): 2909, 1709, 1615, 1305, 1120, 783 cm-1; 1H-NMR 
(CDCl3) δ (ppm): 3.82 (s, 3H, CH3O), 6.99 (d, J = 7.5 Hz, 1H), 7.03 (d, J = 7.4 Hz, 1H), 7.24 (d,  
J = 8.4 Hz, 1H), 7.36 (m, 2H), 7.60 (m, 2H), 7.66 (s, 1H); 13C-NMR (CDCl3) δ (ppm): 55.7, 111.3, 
116.7, 118.2, 120.6, 121.0, 123.5, 127.6, 130.0, 130.5, 130.7, 133.8, 140.2, 152.5, 157.1, 159.6; MS 
m/z (%): 332 ([M+2]+, 100), 330 (M+, 97), 315(23), 237 (32), 152 (15), 118 (16); Anal. Calcd for 
C16H11BrO3: C, 58.03; H, 3.35. Experimental: C, 58.25; H, 3.49. 
 
6-Bromo-3-(3’-methoxy)phenylcoumarin (10). Purified by chromatography using 9:1 hexane/ethyl 
acetate as eluent; Mp: 148-150 ºC; IR (KBr): 2898, 1700, 1620, 1300, 1110, 789 cm-1; 1H-NMR 
(CDCl3) δ (ppm): 3.85 (s, 3H, CH3O), 6.96 (dd, J = 2.3; 8.2 Hz, 1H), 7.20 (m, 2H), 7.36 (m, 2H), 7.60 
(d, J = 8.3 Hz, 1H), 7.75 (s, 1H), 7.85 (s, 1H); 13C-NMR (CDCl3) δ (ppm): 55.2, 114.1, 114.6, 116.9, 
118.0, 120.7, 121.0, 129.0, 129.4, 130.0, 133.9, 135.3, 138.3, 152.1, 159.3, 159.6; MS m/z (%): 332 
([M+2]+, 100), 330 (M+, 28), 302(34), 195 (10), 180 (10), 152 (17); Anal. Calcd for C16H11BrO3: C, 
58.03; H, 3.35. Experimental: C, 58.15; H, 3.50. 
 
6-Bromo-3-(4’-methoxy)phenylcoumarin (11). Purified by chromatography using 9:1 hexane/ethyl 
acetate as eluent; Mp: 205–206 ºC; IR (KBr): 2900, 1712, 1612, 1298, 1110, 781 cm-1; 1H-NMR 
(CDCl3) δ (ppm): 3.85 (s, 3H, CH3O), 6.97 (d, J = 8.8 Hz, 2H), 7.23 (m, 1H), 7.57 (dd, J = 2.2, 8.7 Hz, 
1H), 7.63 (m, 3H), 7.67 (s, 1H); 13C-NMR (CDCl3) δ (ppm): 55.3, 113.9 (2C), 114.1, 116.9, 118.1, 
121.4, 126.5, 128.9, 129.8 (2C), 129.9, 133.6, 136.8, 152.0, 160.4; MS m/z (%): 332 ([M+2]+, 100), 
330 (M+, 13), 302(12), 288 (40), 259 (18), 195 (10), 180 (17), 152 (14); Anal. Calcd for C16H11BrO3: 
C, 58.03; H, 3.35. Experimental: C, 58.15; H, 3.42. 
 
6-Chloro-3-(2’-hydroxy)phenylcoumarin (12). Purified by chromatography using 8:2 hexane/ethyl 
acetate as eluent. Mp: 225–227 ºC. IR (KBr): 3500, 2920, 1705, 1613, 1300, 1120, 780 cm-1. 1H NMR 
(DMSO-d6) δ (ppm): 6.86 (m, 2H), 7.23 (m, 2H), 7.39 (d, J = 8.8 Hz, 1H), 7.78 (dd, J = 2.3; 8.8 Hz, 
1H), 7.97 (s, 1H), 8.00 (s, 1H), 9.64 (bs, 1H, 1OH). 13C NMR (DMSO-d6) δ (ppm): 115.7, 116.0, 
118.2, 118.7, 121.2, 121.8, 127.1, 129.9, 130.3, 130.7, 133.8, 140.6, 140.7, 152.1, 155.1. MS m/z (%): 
274 ([M+2]+, 23), 272 (M+, 100), 244(35), 180 (19), 152 (20), 118 (10). Anal. Calcd for C15H9ClO3: C, 
66.07; H, 3.33. Experimental: C, 66.25; H, 3.49. 
 
6-Chloro-3-(3’-hydroxy)phenylcoumarin (13). Purified by chromatography using 8:2 hexane/ethyl 
acetate as eluent; Mp: 221–223 ºC; IR (KBr): 3502, 2925, 1701, 1614, 1310, 1110, 785 cm-1; 1H-NMR 
(DMSO-d6) δ (ppm): 6.82 (dd, J = 2.2; 8.0 Hz, 1H), 7.10 (m, 2H), 7.25 (m, 1H), 7.44 (d, J = 8.8 Hz, 
1H), 7.61 (dd, J = 2.5; 8.8 Hz, 1H), 7.86 (d, J = 2.5 Hz, 1H), 8.14 (s, 1H), 9.60 (bs, 1H, 1OH); 13C- 
NMR (DMSO-d6) δ (ppm): 115.5, 115.9, 117.8, 119.2, 120.9, 127.6, 128.0, 128.2, 129.3, 131.1, 135.5, 
139.1, 151.5, 157.1, 159.2; MS m/z (%): 274 ([M+2]+, 21), 272 (M+, 100), 244(48), 180 (14), 152 (23), 
118 (10); Anal. Calcd for C15H9ClO3: C, 66.07; H, 3.33. Experimental: C, 66.30; H, 3.45. 
 
6-Chloro-3-(4’-hydroxy)phenylcoumarin (14). Purified by chromatography using 8:2 hexane/ethyl 
acetate as eluent; Mp: 241–243 ºC; IR (KBr): 3500, 2918, 1708, 1610, 1296, 1119, 783 cm-1; 1H-NMR 




(DMSO-d6) δ (ppm): 6.84 (d, J = 8.6 Hz, 2H), 7.44 (d, J = 8.8 Hz, 1H), 7.58 (m, 3H), 7.84 (d,  
J = 2.5 Hz, 1H), 8.09 (s, 1H), 9.81 (bs, 1H, 1OH); 13C-NMR (DMSO-d6) δ (ppm): 115.1 (2C), 117.7, 
121.1, 124.8, 127.2, 127.8, 128.1, 129.9 (2C), 130.6, 137.1, 151.2, 158.2, 159.5; MS m/z (%): 274 
([M+2]+, 20), 272 (M+, 100), 244(74), 180 (15), 152 (40), 118 (5); Anal. Calcd for C15H9ClO3: C, 
66.07; H, 3.33. Experimental: C, 66.22; H, 3.47. 
 
6-Bromo-3-(2’-hydroxy)phenylcoumarin (15). Purified by chromatography using 8:2 hexane/ethyl 
acetate as eluent; Mp: 230–232 ºC; IR (KBr): 3510, 2918, 1709, 1620, 1310, 1120, 780 cm-1; 1H-NMR 
(DMSO-d6) δ (ppm): 6.87 (m, 2H), 7.23 (m, 2H), 7.40 (d, J = 8.8 Hz, 1H), 7.74 (dd, J = 2.3; 8.8 Hz, 
1H), 7.99 (s, 1H), 8.02 (s, 1H), 9.64 (bs, 1H, 1OH); 13C-NMR (DMSO-d6) δ (ppm): 115.7, 116.0, 
118.2, 118.7, 121.2, 121.8, 127.1, 129.9, 130.3, 130.7, 133.8, 140.6, 152.1, 155.1, 158.8; MS m/z (%): 
318 ([M+2]+, 47), 316 (M+, 71), 300(8), 288 (40), 180 (54), 152 (100); Anal. Calcd for C15H9BrO3: C, 
56.81; H, 2.86. Experimental: C, 56.95; H, 3.00. 
 
6-Bromo-3-(3’-hydroxy)phenylcoumarin (16). Purified by chromatography using 8:2 hexane/ethyl 
acetate as eluent; Mp: 219–221 ºC; IR (KBr): 3505, 2919, 1709, 1622, 1312, 1123, 780 cm-1; 1H-NMR 
(DMSO-d6) δ (ppm): 6.82 (dd, J = 2.0; 7.7 Hz, 1H), 7.10 (m, 2H), 7.25 (m, 1H), 7.38 (d, J = 8.8 Hz, 
1H), 7.73 (dd, J = 2.3; 8.8 Hz, 1H), 8.00 (d, J = 2.3 Hz, 1H), 8.14 (s, 1H), 9.59 (bs, 1H, 1OH); 13C- 
NMR (DMSO-d6) δ (ppm): 115.5, 115.9, 116.1, 118.1, 119.2, 121.4, 128.0, 129.3, 130.6, 133.9, 135.5, 
139.0, 151.9, 157.1, 159.1; MS m/z (%): 318 ([M+2]+, 46), 316 (M+, 79), 288 (46), 180 (19), 152 
(100); Anal. Calcd for C15H9BrO3: C, 56.81; H, 2.86. Experimental: C, 56.98; H, 3.01. 
 
6-Bromo-3-(4’-hydroxy)phenylcoumarin (17). Purified by chromatography using 8:2 hexane/ethyl 
acetate as eluent; Mp: 226–228 ºC; IR (KBr): 3520, 2939, 1710, 1622, 1302, 1133, 784 cm-1; 1H-NMR 
(DMSO-d6) δ (ppm): 6.84 (d, J = 8.8 Hz, 2H), 7.34 (d, J = 9.1 Hz, 1H), 7.54 (d, J = 8.8 Hz, 2H), 7.66 
(m, 1H), 7.99 (s, 1H), 8.09 (s, 1H), 9.81 (bs, 1H, 1OH); 13C-NMR (DMSO-d6) δ (ppm): 115.1 (2C), 
116.0, 118.0, 121.6, 124.8, 127.7, 129.9 (2C), 130.2, 133.3, 137.0, 151.6, 158.2, 159.4; MS m/z (%): 
318 ([M+2]+, 31), 317 ([M+1]+, 100), 316 (M+, 40), 288 (39), 180 (14), 152 (46); Anal. Calcd for 
C15H9BrO3: C, 56.81; H, 2.86. Experimental: C, 56.87; H, 3.0. 
 
3.3. Vasorelaxant activity 
 
Vascular rings were prepared from aortae of male or female Wistar rats weighing 230–270 g. After 
an equilibration period of at least 1 h, isometric contractions induced by PE (1 μM) were obtained. 
When contraction of the tissue in response to the corresponding vasoconstrictor agent had stabilized 
(after about 20 min), cumulatively increasing concentrations of the compounds were added to the bath 
at 15–20 min intervals (the time needed to obtain steady-state relaxation). Control tissues were 
subjected to the same procedure simultaneously, but in this case omitting the compounds and adding 
the vehicle [appropriate dilutions of dimethylsulfoxide (DMSO)]. Results shown in the tables are 
expressed as means ± SEM from five experiments. Means were compared by one-way analysis of 
variance (ANOVA) followed by Dunnett’s post hoc test. The inhibitory effects of the tested 
compounds in rat aorta and human platelet are expressed as IC50 (concentrations that produce a 50% 




inhibition) estimated by least-squares linear regression using the program Origin 5.0, with  
X = log molar concentration of the tested compounds and Y = % of pharmacological response. 
 
3.4. Antiplatelet activity 
 
Preparation of washed platelets. Washed human platelets were prepared from blood anticoagulated 
with citrate-phosphate-dextrose, which was obtained from Centro de Transfusion de Galicia (Santiago 
de Compostela, Spain). Bags containing buffy coat from individual donors were diluted with the same 
volume of washing buffer (NaCl, 120 mM; KCl, 5 mM; trisodium citrate, 12 mM; glucose, 10 mM; 
sucrose, 12.5 mM; pH 6) and centrifuged at 400 g for 9 min. The upper layer containing platelet 
(platelet-rich plasma) was removed and centrifuged at 400 g for 9 min. The resulting platelet pellet 
was recovered, resuspended with washing buffer, and centrifuged again at 1,000 g for 15 min. Finally, 
the platelet pellet from this step was resuspended in a modified Tyrode-HEPES buffer (HEPES,  
10 mM; NaCl, 140 mM; KCl, 3 mM; MgCl2, 0.5 mM; NaHCO3, 5 mM; glucose, 10 mM; pH 7.4) to 
afford a cell density of 2.5–3.5 × 108 platelet/mL. The calcium concentration in the extracellular 
medium was 2 mM.  
Platelet aggregation studies. Platelet aggregation was measured using a dual channel aggregometer 
(Chrono-log, Havertown, PA, USA). Each tested compound, dissolved in DMSO, was incubated with 
washed platelet at 37 °C for 5 min. Stimulus (thrombin) was then added to induce platelet aggregation 
and the light transmission was monitored over 5 min period. Platelet aggregation is measured as the 
maximum change in light transmission during this period. The 100% aggregation value was obtained 
when vehicle (DMSO) was added instead of the compounds. The final DMSO concentration was 
below 1% (v/v) in all cases.  
4. Conclusions  
In conclusion, some of the new synthesized molecules have been characterized as agents with 
remarkable human platelet antiaggregatory activity and significant vasorelaxant effects in intact rat 
aorta. Further experiments are in progress aimed at providing new data to clarify the precise 
mechanism by which coumarin-resveratrol hybrid derivatives produce their characteristic vasorelaxant 
and platelet antiaggregatory effects. 
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